Insights into cell ontogeny, age, and acute myeloid leukemia

Experimental Hematology

Volumn 43, Issue 9, 2015, Pages 745-755

  Chaudhury, Shahzya S ^a   Morison, Jessica K ^a   Gibson, Brenda E S ^b   Keeshan, Karen ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORE BINDING FACTOR BETA; DNA; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; NUCLEOPORIN 98; PHOSPHATIDYLINOSITOL 3 KINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; RAS PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE MYELOBLASTIC LEUKEMIA; AGE; CANCER PROGNOSIS; CANCER REGRESSION; CELL AGING; CHILD; CHILDHOOD LEUKEMIA; CHILDHOOD MORTALITY; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CYTOLOGY; DISEASE FREE SURVIVAL; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; ONTOGENY; OVERALL SURVIVAL; PHENOTYPE; PRELEUKEMIA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGING; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; INFANT; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGING; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE;

EID: 84940452652     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.05.008     Document Type: Review

References (104)

1. SEER Cancer Statistics Review, 1975-2011 2014, National Institutes of Health, Bethesda, MD, Updated 17 December. Available at:. http://seer.cancer.gov/archive/csr/1975_2011/, N.N.A. Howlader, M. Krapcho, J. Garshell (Eds.).
2. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 1998, 92:2322-2333.
3. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
4. Creutzig U., Zimmermann M., Bourquin J.P., et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004. Blood 2013, 122:37-43.
5. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
6. Burnett A.K., Hills R.K., Milligan D.W., et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 2010, 28:586-595.
7. Gibson B.E., Webb D.K., Howman A.J., et al. Results of a randomized trial in children with acute myeloid leukaemia: Medical research council AML12 trial. Br J Haematol 2011, 155:366-376.
8. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
9. Creutzig U., Buchner T., Sauerland M.C., et al. Significance of age in acute myeloid leukemia patients younger than 30 years: A common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008, 112:562-571.
10. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009, 114:937-951.
11. Creutzig U., van den Heuvel-Eibrink M.M., Gibson B., et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood 2012, 120:3187-3205.
12. Harrison C.J., Hills R.K., Moorman A.V., et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010, 28:2674-2681.
13. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?. Blood 2007, 109:3658-3666.
14. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
15. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
16. Niewerth D., Creutzig U., Bierings M.B., Kaspers G.J. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010, 116:2205-2214.
17. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
18. Von Neuhoff C., Reinhardt D., Sander A., et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010, 28:2682-2689.
19. Balgobind B.V., Raimondi S.C., Harbott J., et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: Results of an international retrospective study. Blood 2009, 114:2489-2496.
20. Hollink I.H., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T., et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011, 118:3645-3656.
21. Gruber T.A., Larson Gedman A., Zhang J., et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell 2012, 22:683-697.
22. Tosi S., Harbott J., Teigler-Schlegel A., et al. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2000, 29:325-332.
23. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
24. Meshinchi S., Woods W.G., Stirewalt D.L., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
25. Schneider F., Hoster E., Schneider S., et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2012, 91:9-18.
26. Thiede C., Koch S., Creutzig E., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107:4011-4020.
27. Brown P., McIntyre E., Rau R., et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007, 110:979-985.
28. Hollink I.H., Zwaan C.M., Zimmermann M., et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009, 23:262-270.
29. Green C.L., Koo K.K., Hills R.K., Burnett A.K., Linch D.C., Gale R.E. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28:2739-2747.
30. Ho P.A., Alonzo T.A., Gerbing R.B., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. Blood 2009, 113:6558-6566.
31. Taskesen E., Bullinger L., Corbacioglu A., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117:2469-2475.
32. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
33. Thol F., Damm F., Ludeking A., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
34. Ho P.A., Kutny M.A., Alonzo T.A., et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group. Pediatr Blood Cancer 2011, 57:204-209.
35. Thol F., Heuser M., Damm F., Klusmann J.H., Reinhardt K., Reinhardt D. DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 2011, 96:1238-1240.
36. Ford A.M., Ridge S.A., Cabrera M.E., et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993, 363:358-360.
37. Gale K.B., Ford A.M., Repp R., et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997, 94:13950-13954.
38. Pine S.R., Guo Q., Yin C., Jayabose S., Druschel C.M., Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 2007, 110:2128-2131.
39. Heald B., Hilden J.M., Zbuk K., et al. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nat Clin Pract Oncol 2007, 4:433-438.
40. Zipursky A., Brown E., Christensen H., Sutherland R., Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997, 21:97-101.
41. Al-Kasim F., Doyle J.J., Massey G.V., Weinstein H.J., Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002, 24:9-13. Pediatric Oncology Group.
42. Gurbuxani S., Vyas P., Crispino J.D. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004, 103:399-406.
43. Massey G.V., Zipursky A., Chang M.N., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006, 107:4606-4613.
44. Klusmann J.H., Creutzig U., Zimmermann M., et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008, 111:2991-2998.
45. Gamis A.S., Alonzo T.A., Gerbing R.B., et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group Study A2971. Blood 2011, 118:6752-6759. quiz 6996.
46. Ahmed M., Sternberg A., Hall G., et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004, 103:2480-2489.
47. Chessells J.M. Leukaemia in the young child. Br J Cancer Suppl 1992, 18:S54-S57.
48. Pui C.H., Kane J.R., Crist W.M. Biology and treatment of infant leukemias. Leukemia 1995, 9:762-769.
49. Carroll A., Civin C., Schneider N., et al. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A Pediatric Oncology Group Study. Blood 1991, 78:748-752.
50. Creutzig U., Zimmermann M., Bourquin J.P., et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: An AML-BFM study group report. Leukemia 2012, 26:654-661.
51. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.
52. Wang J., Iwasaki H., Krivtsov A., et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005, 24:368-381.
53. Schoch C., Schnittger S., Klaus M., Kern W., Hiddemann W., Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102:2395-2402.
54. Meyer C., Hofmann J., Burmeister T., et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013, 27:2165-2176.
55. Horton S.J., Jaques J., Woolthuis C., et al. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia 2013, 27:1116-1126.
56. Magee J.A., Ikenoue T., Nakada D., Lee J.Y., Guan K.L., Morrison S.J. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 2012, 11:415-428.
57. Babovic S., Eaves C.J. Hierarchical organization of fetal and adult hematopoietic stem cells. Exp Cell Res 2014, 329:185-191.
58. Rebel V.I., Miller C.L., Eaves C.J., Lansdorp P.M. The repopulation potential of fetal liver hematopoietic stem cells in mice exceeds that of their liver adult bone marrow counterparts. Blood 1996, 87:3500-3507.
59. Bowie M.B., Kent D.G., Dykstra B., et al. Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. Proc Natl Acad Sci U S A 2007, 104:5878-5882.
60. Sudo K., Ema H., Morita Y., Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med 2000, 192:1273-1280.
61. Dykstra B., Olthof S., Schreuder J., Ritsema M., de Haan G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med 2011, 208:2691-2703.
62. Benz C., Copley M.R., Kent D.G., et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 2012, 10:273-283.
63. McKinney-Freeman S., Cahan P., Li H., et al. The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell 2012, 11:701-714.
64. Sun D., Luo M., Jeong M., et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 2014, 14:673-688.
65. Flach J., Bakker S.T., Mohrin M., et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature 2014, 512:198-202.
66. Santos M.A., Faryabi R.B., Ergen A.V., et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature 2014, 514:107-111.
67. Holyoake T.L., Nicolini F.E., Eaves C.J. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Exp Hematol 1999, 27:1418-1427.
68. Pang W.W., Price E.A., Sahoo D., et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A 2011, 108:20012-20017.
69. Rufer N., Brummendorf T.H., Dragowska V., Shultzer M., Wadsworth L.D., Lansdorp P.M. Turnover of stem cells, naive and memory T lymphocytes, estimated from telomere fluorescence measurements. Cytotherapy 1999, 1:342.
70. Sidorov I., Kimura M., Yashin A., Aviv A. Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth. Exp Hematol 2009, 37:514-524.
71. Rube C.E., Fricke A., Widmann T.A., et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One 2011, 6:e17487.
72. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
73. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628.
74. Haferlach T., Kohlmann A., Wieczorek L., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
75. De Jonge H.J., Valk P.J., Veeger N.J., et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116:1747-1754.
76. Ross M.E., Mahfouz R., Onciu M., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004, 104:3679-3687.
77. Balgobind B.V., Van den Heuvel-Eibrink M.M., De Menezes R.X., et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011, 96:221-230.
78. Genovese G., Kahler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014, 371:2477-2487.
79. Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014, 371:2488-2498.
80. Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014, 20:1472-1478.
81. Shlush L.I., Zandi S., Mitchell A., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014, 506:328-333.
82. Jan M., Snyder T.M., Corces-Zimmerman M.R., et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012, 4:149ra118.
83. Corces-Zimmerman M.R., Hong W.J., Weissman I.L., Medeiros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 2014, 111:2548-2553.
84. Majeti R. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. Best Pract Res Clin Haematol 2014, 27:229-234.
85. Chan S.M., Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013, 98:648-657.
86. Tie R., Zhang T., Fu H., et al. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: A systematic review and meta-analysis. PLoS One 2014, 9:e93353.
87. Yan X.J., Xu J., Gu Z.H., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43:309-315.
88. Yamashita Y., Yuan J., Suetake I., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723-3731.
89. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
90. Thol F., Friesen I., Damm F., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011, 29:2499-2506.
91. Liang D.C., Liu H.C., Yang C.P., et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood 2013, 121:2988-2995.
92. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
93. Abdel-Wahab O., Levine R.L. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013, 121:3563-3572.
94. Gaidzik V.I., Paschka P., Spath D., et al. TET2 mutations in acute myeloid leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012, 30:1350-1357.
95. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
96. Weissmann S., Alpermann T., Grossmann V., et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012, 26:934-942.
97. Metzeler K.H., Becker H., Maharry K., et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011, 118:6920-6929.
98. Busque L., Patel J.P., Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012, 44:1179-1181.
99. Huether R., Dong L., Chen X., et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun 2014, 5:3630.
100. Ribeiro A.F., Pratcorona M., Erpelinck-Verschueren C., et al. Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia. Blood 2012, 119:5824-5831.
101. Juhl-Christensen C., Ommen H.B., Aggerholm A., et al. Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatr Blood Cancer 2012, 58:525-531.
102. Wiemels J.L., Xiao Z., Buffler P.A., et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002, 99:3801-3805.
103. Greaves M.F., Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003, 3:639-649.
104. Miyamoto T., Weissman I.L., Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000, 97:7521-7526.